Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Source: Globenewswire
Clinical Trial Results: The INSIGHT-003 trial reported a 60.8% response rate and a 90.2% disease control rate in patients with advanced non-small cell lung cancer (NSCLC) using a combination of eftilagimod alpha, KEYTRUDA®, and chemotherapy, showing significant improvements over historical controls.
Patient Demographics: Approximately 92% of evaluable patients had PD-L1 Tumor Proportion Scores (TPS) below 50%, highlighting a critical area of unmet need, particularly as the treatment demonstrated strong efficacy even among those with low PD-L1 expression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
